Independent Advisor Alliance Has $2.93 Million Position in Stryker Co. (NYSE:SYK)

Independent Advisor Alliance boosted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 19.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,149 shares of the medical technology company's stock after acquiring an additional 1,325 shares during the quarter. Independent Advisor Alliance's holdings in Stryker were worth $2,934,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Assetmark Inc. raised its stake in shares of Stryker by 30.7% in the third quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company's stock valued at $366,000 after acquiring an additional 238 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of Stryker by 4.2% during the third quarter. Harbour Investments Inc. now owns 6,330 shares of the medical technology company's stock worth $2,287,000 after purchasing an additional 256 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Stryker in the third quarter valued at about $362,000. Savvy Advisors Inc. grew its holdings in Stryker by 29.7% during the 3rd quarter. Savvy Advisors Inc. now owns 1,388 shares of the medical technology company's stock worth $501,000 after acquiring an additional 318 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new stake in Stryker in the 3rd quarter valued at about $493,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research analyst reports. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Barclays lifted their target price on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. JPMorgan Chase & Co. lifted their price objective on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Finally, Argus set a $450.00 price objective on Stryker in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.90.

Remove Ads

Stryker Stock Down 0.0 %

SYK stock traded down $0.05 during mid-day trading on Thursday, hitting $363.79. 1,965,827 shares of the company were exchanged, compared to its average volume of 1,221,728. The firm has a market cap of $138.81 billion, a P/E ratio of 46.88, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm's 50 day simple moving average is $382.87 and its 200 day simple moving average is $373.26.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 EPS. On average, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.